News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Trading in PledPharma’s shares commences today on the Nasdaq Stockholm main market

October 31, 2019

PledPharma AB (publ) announces today the commencement of trading in the company’s shares on Nasdaq Stockholm's main market.

“I am very happy and proud that we are now moving up to Nasdaq Stockholm’s main market. The listing is an important milestone for PledPharma that can both help create further interest from a broader investor base and reflect the maturity of our business and our global ambitions,” said Nicklas Westerholm, CEO of PledPharma.

The shares will be traded on the Nasdaq Stockholm main market under the same ticker (PLED) and ISIN-code (SE0003815604). There is no fund raising or new share issue in connection with the list change, and shareholders in PledPharma do not need to take any actions.

Pareto Securities AB and Advokatfirman Lindahl KB are PledPharma’s financial and legal advisers respectively, in connection with the listing.



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10